<http://schema.org/articleBody>
"&amp;lt;p&amp;gt;The anti-inflammatory drug Humira was not only the best-selling biologic; it was the best-selling drug worldwide, regardless of class.\u00A0&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Indications:&amp;lt;/strong&amp;gt; Rheumatoid arthritis, plaque psoriasis, Crohn&amp;amp;#39;s disease,\u00A0 ulcerative colitis, ankylosing spondylitis; psoriatic arthritis, polyarticular juvenile idiopathic arthritis&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Manufacturer: &amp;lt;/strong&amp;gt;AbbVie, an Abbott Laboratories spin-off&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Global Sales in 2014: &amp;lt;/strong&amp;gt;$13 billion&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Generic name: &amp;lt;/strong&amp;gt;Adalimumab&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Launch date:&amp;lt;/strong&amp;gt; 2002&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Remicade was originally developed by Centocor Ortho Biotech, which is now Janssen Biotech, a Johnson &amp;amp;amp; Johnson subsidiary.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Indications: &amp;lt;/strong&amp;gt;Rheumatoid arthritis, Crohn&amp;amp;#39;s disease, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Manufacturer: &amp;lt;/strong&amp;gt;Johnson &amp;amp;amp; Johnson/Merck &amp;amp;amp; Co.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Global Sales in 2014:&amp;lt;/strong&amp;gt; $10.1 billion&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Generic name:&amp;lt;/strong&amp;gt; Infliximab&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Launch date: &amp;lt;/strong&amp;gt;1998&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Rituxan (rituximab) was developed by IDEC Pharmaceuticals under the name IDEC-C2B8. Rituxan is currently co-marketed in the United States by Biogen Idec and Roche subsidiary Genentech.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Indication: &amp;lt;/strong&amp;gt;Non-Hodgkins lymphoma, chronic lymphocytic leukemia,\u00A0 rheumatoid arthritis&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Manufacturer: &amp;lt;/strong&amp;gt;Roche&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Global Sales in 2014: &amp;lt;/strong&amp;gt;$7.3 billion&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Generic name:&amp;lt;/strong&amp;gt; Rituximab&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Launch date: &amp;lt;/strong&amp;gt;1997&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Etanercept was developed by researchers at Immunex. Today the drug is co-marketed in North America by Amgen and Pfizer, by Takeda Pharmaceuticals in Japan and by Wyeth in the rest of the world.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Indication: &amp;lt;/strong&amp;gt;Rheumatoid arthritis, plaque psoriasis, psoriatic arthritis&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Manufacturer: &amp;lt;/strong&amp;gt;Pfizer/Amgen&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Global Sales in 2014: &amp;lt;/strong&amp;gt;$9.1 billion&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Generic name: &amp;lt;/strong&amp;gt;Etanercept&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Launch date: &amp;lt;/strong&amp;gt;1998&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Lantus was developed at Sanofi-Aventis&amp;amp;#39;s biotechnology research center in Frankfurt-H\u00F6chst, Germany.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Indication: &amp;lt;/strong&amp;gt;Diabetes&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Manufacturer: &amp;lt;/strong&amp;gt;Sanofi&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Global Sales in 2014: &amp;lt;/strong&amp;gt;$8.1\u00A0billion&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Generic name: &amp;lt;/strong&amp;gt;Insulin glargine [rDNA origin] injection&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Launch date: &amp;lt;/strong&amp;gt;2000&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;When launched in 2004, Genentech&amp;amp;#39;s Avastin was one of the most expensive drugs on the market, with a $4,400 monthly price tag.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Indication: &amp;lt;/strong&amp;gt;Breast, colorectal, kidney, non-small-cell lung,&amp;lt;strong&amp;gt; &amp;lt;/strong&amp;gt;glioblastoma, ovarian cancers&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Manufacturer: &amp;lt;/strong&amp;gt;Roche&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Global Sales in 2014: &amp;lt;/strong&amp;gt;$6.8 billion&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Generic name: &amp;lt;/strong&amp;gt;Bevacizumab&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;\u00A0&amp;lt;strong&amp;gt;Launch date: &amp;lt;/strong&amp;gt;2004&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Herceptin was developed by Genentech, now a Roche subsidiary, and the University of Californa-Los Angeles&amp;amp;#39;\u00A0Jonsson Comprehensive Cancer Center.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Indication:\u00A0 &amp;lt;/strong&amp;gt;HER2&amp;amp;#43; breast cancer&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Manufacturer: &amp;lt;/strong&amp;gt;Roche&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Global Sales in 2014: &amp;lt;/strong&amp;gt;$6.6 billion&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Generic name: &amp;lt;/strong&amp;gt;Trastuzumab&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;\u00A0&amp;lt;strong&amp;gt;Launch date:&amp;lt;/strong&amp;gt; 1998&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Indication: &amp;lt;/strong&amp;gt;Neutropenia related to cancer chemotherapy&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Manufacturer: &amp;lt;/strong&amp;gt;Amgen&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Global Sales in 2014: &amp;lt;/strong&amp;gt;$4.6 billion&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Generic name: &amp;lt;/strong&amp;gt;Pegfilgrastim&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Launch date: &amp;lt;/strong&amp;gt;2002&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Developed by Genentech,\u00A0ranibizumab, an injectable, is marketed in the United States by Genentech and by Novartis outside the U.S.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Indication: &amp;lt;/strong&amp;gt;Age-related macular degeneration&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Manufacturer: &amp;lt;/strong&amp;gt;Roche, Novartis&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Global Sales in 2014: &amp;lt;/strong&amp;gt;$4.2 billion&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Generic name: &amp;lt;/strong&amp;gt;Ranibizumab&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Launch date:&amp;lt;/strong&amp;gt; 2006&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Avonex is marketed in the United States by\u00A0Biogen Idec and by\u00A0Merck under the brand name Rebif.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;Gemany&amp;amp;#39;s Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB and CinnaGen Company cloned Interferon beta-1a and since 2006 the drug has been sold as CinnoVex, a biosimilar, in Iran.&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Indication: &amp;lt;/strong&amp;gt;&amp;lt;a href=&amp;quot;https://www.thebalance.com/top-biologic-drugs-2663233&amp;quot; data-component=&amp;quot;link&amp;quot; data-source=&amp;quot;inlineLink&amp;quot; data-type=&amp;quot;internalLink&amp;quot; data-ordinal=&amp;quot;1&amp;quot;&amp;gt;Multiple sclerosis (MS)&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Manufacturer: &amp;lt;/strong&amp;gt;Biogen Idec&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Global Sales in 2014: &amp;lt;/strong&amp;gt;$3 billion&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Generic name: &amp;lt;/strong&amp;gt;Interferon beta-1a&amp;lt;/p&amp;gt;&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Launch date:&amp;lt;/strong&amp;gt; 1996&amp;lt;/p&amp;gt;"^^<http://www.w3.org/2001/XMLSchema#string>
<https://www.thebalance.com/top-biologic-drugs-2663233>